Curis Lifesciences Reports Financial Results for Half Year and Year Ended March 31, 2026

Curis Lifesciences Reports Financial Results for Half Year and Year Ended March 31, 2026​

Curis Lifesciences Limited announced the approval of its Audited Standalone Financial Results for the half year and year ended March 31, 2026, following a Board meeting held on May 30, 2026.

The company's financial reporting covers comprehensive performance metrics across its profit and loss account, balance sheet, and cash flow statement, reflecting operational results and capital structure changes for the reported periods.

Financial Performance Overview​

The audited statement of profit and loss shows the company's top-line revenue and profitability trends. For the half year ended March 31, 2026, the Total Income stood at 3300.03 Lakhs, compared to 3437.34 Lakhs in the half year ended March 31, 2025.

Key figures from the Profit and Loss Statement (Rs. in Lakhs) are presented below:


The Profit/(loss) for the half year for the period ended March 31, 2026, was 270.55 Lakhs.

Balance Sheet Status​

As of March 31, 2026, the company recorded total Equity and Liabilities of 8152.07 Lakhs, significantly higher than the 4259.52 Lakhs recorded on the same date in the previous year.

The financial position summary (Rs. in Lakhs):

Cash Flow Analysis​

The company's cash flow statements detail cash usage and generation across operating, investing, and financing activities.

In the year ended March 31, 2026, the net cash flow from operating activities was (1641.60) Lakhs. This compares to (203.16) Lakhs for the year ended March 31, 2025.

However, the cash flow from financing activities remained a substantial positive contributor, reporting 2086.61 Lakhs for the year ended March 31, 2026, compared to 194.12 Lakhs in the previous year.

Overall, the net increase in Cash and cash equivalents stood at 286.16 Lakhs for the year ended March 31, 2026, reaching a year-end balance of 316.51 Lakhs.

Key Corporate Developments​

The company noted several significant operational and capital market events. Curis Lifesciences Limited successfully completed its Initial Public Offering (IPO), with equity shares listed on the SME Emerge Platform of NSE Limited on November 14, 2025.

Furthermore, the company confirmed a strategic investment by agreeing to acquire a 51% stake in Uninova Lifesciences Private Limited through a share purchase agreement. For this acquisition, the company has already provided 20.655 Lakhs to the promoters.

CURIS Stock Price Movement​

Shares of Curis Lifesciences Limited on Friday slipped by 3.16% to close at ₹118.00, shedding ₹3.85 from its prior close. The equity recorded a total volume of 13,000 shares, which contributed to the lower settling figure.